Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Sigilon Therapeutics, Inc. SGTX
$0.50
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
18830686.00000000
-
week52high
1.61
-
week52low
0.29
-
Revenue
12944000
-
P/E TTM
0
-
Beta
0.82368200
-
EPS
-1.16000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Canaccord Genuity | Buy | Buy | 23 дек 2021 г. |
| Barclays | Overweight | Overweight | 01 дек 2021 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 30 ноя 2021 г. |
| Jefferies | Hold | Buy | 30 ноя 2021 г. |
| BTIG | Buy | 29 окт 2021 г. | |
| Canaccord Genuity | Buy | 18 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Patel Kavita | A | 8888 | 8888 | 26 мая 2022 г. |
| RUFFOLO ROBERT R | A | 8888 | 8888 | 26 мая 2022 г. |
| Oesterle Stephen N. | A | 8888 | 8888 | 26 мая 2022 г. |
| Shaff Eric D. | A | 8888 | 8888 | 26 мая 2022 г. |
| Yuan Qing Sarah | A | 120000 | 120000 | 01 апр 2022 г. |
| Orfali May | A | 10000 | 10000 | 18 февр 2022 г. |
| Pontes Josias | A | 60000 | 60000 | 18 февр 2022 г. |
| Ashton-Rickardt Philip | A | 90000 | 90000 | 18 февр 2022 г. |
| Vivaldi Coelho Rogerio | A | 230000 | 230000 | 18 февр 2022 г. |
| Vivaldi Coelho Rogerio | A | 400000 | 400000 | 03 янв 2022 г. |
Новостная лента
Sigilon Therapeutics, Inc. (SGTX) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research
04 авг 2022 г. в 19:33
Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of 4.35% and 22.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?